Clinical Trial

Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)

Study acronym: PERCIMEL
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
PERCIMEL is an open multicentric study. The purpose of this study is to assess the interest of molecular analysis on circulating tumor DNA in the follow-up of the disease.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-04-27; most recent amendment 2026-02-05.
Status change: Recruiting → Active, Not Recruiting 2026-02-05
Status change: Not Yet Recruiting → Recruiting 2023-02-01
Trial Details
NCT Number NCT04866680
Lead Sponsor Institut de Cancérologie de Lorraine
Conditions Melanoma
Enrollment 136 participants
Start Date 2023-01-31
Primary Completion 2027-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-09